$PSID currently developing two devices based on the technology: the FireflyDx-Portable, which fits in a backpack and is planned for commercial release in summer 2018; and the FireflyDX-Handheld, which is planned for a commercial launch in 2019, ExcitePCR CMO David Politis said. He added that the technology will detect pathogens in situations where real-time results can prevent infectious diseases from rapidly spreading. GenomeWeb Breaking News: PositiveIDs (PSID) ExcitePCR Subsidiary Aims to Launch Two Versions of POC MDx Platform Over Next Two Years https://ih.advfn.com/p.php?pid=nmona&article=75679141
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.